Chip Simons/Stockbyte via Getty Images Investment Overview I last updated on Viking Therapeutics, Inc. ( VKTX ) in October last year, covering the company's Q3 earnings and business updates, and issued stock with a Buy rating - my sixth straight Buy call, in fact, following notes in September 2024 , December 2024 , April 2025 , July 2025 , and August 2025 . Since December 2024, VKTX stock is in fa...
Chip Simons/Stockbyte via Getty Images Investment Overview I last updated on Viking Therapeutics, Inc. ( VKTX ) in October last year, covering the company's Q3 earnings and business updates, and issued stock with a Buy rating - my sixth straight Buy call, in fact, following notes in September 2024 , December 2024 , April 2025 , July 2025 , and August 2025 . Since December 2024, VKTX stock is in fact down >45%, but up nearly 30% since my April 2025 note, and flat since my December update. I have been following Viking closely because my thesis around the company has been quite consistent. Viking's lead candidate today is VK2735, which is a dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, i.e., a member of the GLP-1 drug class. The best known members of this drug class are Eli Lilly's ( LLY ) tirzepatide, also a GLP/GIP dual agonist, approved to treat obesity and Type 2 Diabetes ("T2D"), brand names Zepbound / Mounjaro, and Novo Nordisk's ( NVO ) semaglutide, which targets GLP-1 only, approved in the same indications as Wegovy / Mounjaro. These drugs' combined sales in 2025 exceeded $70bn. These two drug molecules / four products are still the latest GLP-1 drugs to be approved by the FDA (Zepbound was the last to be approved, in November 2023), despite the best efforts of a range of biotech and pharma companies to develop and win approval for similar drugs, and to grab a slice of what many analysts believe will be the biggest ever pharmaceutical market - treating obese patients or patients with Type 2 diabetes with GLP-1 class drugs. Companies to be aware of in this space include Pharma giants Roche ( RHHBY ), Amgen ( AMGN ), AstraZeneca ( AZN ), AbbVie ( ABBV ), Pfizer ( PFE ), Regeneron ( REGN ) and Merck ( MRK ), and biotechs Altimmune ( ALT ), Structure Therapeutics Inc ( GPCR ), MBX Biosciences Inc ( MBX ), Septerna Inc ( SEPN ), and Zealand Pharma, amongst others. Very few of these companies have advanced th...